Community-Acquired Bacterial Pneumonia (CABP) Archives

First Antibiotic With New Mechanism of Action Approved in Almost 20 Years

Antibiotics, Approvals, Community-Acquired Bacterial Pneumonia (CABP), Emergency Departments, Emergency Rooms, European Medicines Agency (EMA), Fast Track Designation, FDA, FDA/Regulatory, Priority Review, U.S. Centers for Disease Control and Prevention, Wholesale Acquisition Cost

The U.S. FDA gave Nabriva Therapeutics a thumbs-up for the company’s oral and intravenous formulations of Xenleta (lefamulin) to treat community-acquired bacterial pneumonia in adults.

August 20, 2019/by BioSpace

FDA Approves Paratek’s Oral Antibiotic Nuzyra

Acute Bacterial Skin and Skin Structure Infections (ABSSSI), Antibacterials, Antibiotics, Approvals, Biopharmaceutical, Community-Acquired Bacterial Pneumonia (CABP), FDA, FDA/Regulatory, New Drug Approvals

The U.S. FDA approved Paratek Pharmaceuticals Inc.’s Nuzyra (omadacycline) for the treatment of adults with community-acquired bacterial pneumonia and acute skin and skin structure infections.

October 2, 2018/by GlobeNewswire